Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Financial Results (May 7, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 7, 2026
Period End
May 7, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’16Jun ’16
  2. Deal closed8-K · May ’19May ’19
  3. Leadership change8-K · May ’21May ’21
  4. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (NYSE: CRL) reported first-quarter 2026 results on May 7, 2026.

Total revenue was $995.8 milliona, up 1.2% from $984.2 million a year earlier, though organic revenue declined 1.5% after adjusting for a 2.8% foreign currency benefit and a 0.1% divestiture reduction. GAAP results were weak: the company posted a net loss attributable to common shareholders of $(14.8) million, or $(0.30) per diluted share, versus net income of $25.5 million, or $0.50 per share, a year earlier. The decline was principally due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, or $1.53 per share.

Non-GAAP diluted EPS was $2.06b, down 12.0% from $2.34, and non-GAAP operating margin fell to 16.3% from 19.1%. By segment, Research Models and Services (RMS) revenue declined 2.2% reported and 5.5% organically, and Discovery and Safety Assessment (DSA) revenue rose 0.7% reported but fell 1.4% organically. Manufacturing Solutions grew 6.8% reported and 2.9% organically, supported by Microbial Solutions.

The company completed the divestiture of its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026. It repurchased 1.1 million shares for $200.0 millionc in the quarter and had $800.0 million remaining under its $1.0 billion authorization.

CRL reaffirmed its 2026 organic revenue growth guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30d. It lowered its reported revenue growth outlook to (5.5)% to (4.0)% from (5.0)% to (3.5)%, reflecting foreign exchange assumptions, and set GAAP EPS guidance at $5.35 to $5.85.

Key Highlights

  1. Revenue of $995.8 million rose 1.2% reported, but organic revenue declined 1.5%.
  2. GAAP net loss of $(14.8) million, or $(0.30) per diluted share, driven mainly by a $118.0 million ($1.53 per share) loss on assets held for sale for the CDMO and Cell Solutions divestiture.
  3. Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34, and non-GAAP operating margin declined to 16.3% from 19.1%.
  4. RMS organic revenue fell 5.5% and DSA organic revenue fell 1.4%; Manufacturing organic revenue grew 2.9%.
  5. CDMO and Cell Solutions divestiture to GI Partners completed May 6, 2026; sale of certain European Discovery Services sites expected in May 2026.
  6. Reaffirmed 2026 organic revenue and non-GAAP EPS guidance ($10.80 to $11.30), but lowered reported revenue outlook by approximately 50 basis points on FX assumptions.
  7. Repurchased $200.0 million of common stock in Q1 2026, with $800.0 million remaining under the $1.0 billion authorization.

Frequently Asked Questions

  1. Why did GAAP results swing to a loss when operating margin improved?

    GAAP operating margin rose to 12.0% from 7.6%, mainly due to lower accelerated amortization on certain CDMO client relationships. However, a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture was recorded in other expense, producing a GAAP net loss of $(14.8) million, or $(0.30) per diluted share.

  2. Did the company change its 2026 guidance?

    The company reaffirmed its 2026 organic revenue growth guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30. It lowered its reported revenue growth guidance to (5.5)% to (4.0)% from (5.0)% to (3.5)%, reflecting recent foreign exchange assumption changes, and set GAAP EPS guidance at $5.35 to $5.85.

  3. What drove the decline in non-GAAP margins?

    The company attributed the non-GAAP operating margin decline to higher study-related direct costs in DSA, unfavorable revenue mix in RMS, and higher stock-based compensation largely related to an executive transition. Stock-based compensation was $22.4 million in the quarter versus $13.1 million a year earlier.

  4. Which business segments drove performance?

    Manufacturing Solutions was the strongest segment, with reported revenue up 6.8% and organic revenue up 2.9%, led by Microbial Solutions. RMS organic revenue fell 5.5%, mainly from small and large research models, and DSA organic revenue fell 1.4%, driven by discovery services.

  5. How is the company returning capital and reshaping its portfolio?

    The company repurchased 1.1 million shares for $200.0 million in the first quarter and had $800.0 million remaining under its $1.0 billion authorization. It completed the CDMO and Cell Solutions divestiture on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026, with the stated aim of refocusing on core competencies such as regulated drug development testing.